267 related articles for article (PubMed ID: 11422206)
1. Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition.
Wada J; Shintani N; Kikutani K; Nakae T; Yamauchi T; Takechi K
Clin Exp Immunol; 2001 May; 124(2):282-9. PubMed ID: 11422206
[TBL] [Abstract][Full Text] [Related]
2. Experimental autoimmune myositis in SJL/J mice produced by immunization with syngeneic myosin B fraction. Transfer by both immunoglobulin G and T cells.
Matsubara S; Okumura S
J Neurol Sci; 1996 Dec; 144(1-2):171-5. PubMed ID: 8994120
[TBL] [Abstract][Full Text] [Related]
3. Experimental allergic myositis in SJL/J mice immunized with rabbit myosin B fraction: immunohistochemical analysis and transfer.
Matsubara S; Shima T; Takamori M
Acta Neuropathol; 1993; 85(2):138-44. PubMed ID: 8442405
[TBL] [Abstract][Full Text] [Related]
4. Experimental autoimmune myositis in SJL/J mice.
Rosenberg NL; Ringel SP; Kotzin BL
Clin Exp Immunol; 1987 Apr; 68(1):117-29. PubMed ID: 3308207
[TBL] [Abstract][Full Text] [Related]
5. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments.
Basta M; Dalakas MC
J Clin Invest; 1994 Nov; 94(5):1729-35. PubMed ID: 7962520
[TBL] [Abstract][Full Text] [Related]
6. Retinoid ameliorates experimental autoimmune myositis, with modulation of Th cell differentiation and antibody production in vivo.
Ohyanagi N; Ishido M; Suzuki F; Kaneko K; Kubota T; Miyasaka N; Nanki T
Arthritis Rheum; 2009 Oct; 60(10):3118-27. PubMed ID: 19790078
[TBL] [Abstract][Full Text] [Related]
7. Skeletal muscle myosin is the autoantigen for experimental autoimmune myositis.
Nemoto H; Bhopale MK; Constantinescu CS; Schotland D; Rostami A
Exp Mol Pathol; 2003 Jun; 74(3):238-43. PubMed ID: 12782010
[TBL] [Abstract][Full Text] [Related]
8. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.
Barbasso Helmers S; Dastmalchi M; Alexanderson H; Nennesmo I; Esbjörnsson M; Lindvall B; Lundberg IE
Ann Rheum Dis; 2007 Oct; 66(10):1276-83. PubMed ID: 17277004
[TBL] [Abstract][Full Text] [Related]
9. Development of an improved animal model of experimental autoimmune myositis.
Kang J; Zhang HY; Feng GD; Feng DY; Jia HG
Int J Clin Exp Pathol; 2015; 8(11):14457-64. PubMed ID: 26823763
[TBL] [Abstract][Full Text] [Related]
10. Myosin-induced autoimmune polymyositis in the rat.
Kojima T; Tanuma N; Aikawa Y; Shin T; Sasaki A; Matsumoto Y
J Neurol Sci; 1997 Oct; 151(2):141-8. PubMed ID: 9349668
[TBL] [Abstract][Full Text] [Related]
11. FK506 suppressed the inflammatory change of EAM in SJL/J mice.
Nemoto H; Nemoto K; Sugimoto H; Kinoshita M
J Neurol Sci; 2001 Dec; 193(1):7-11. PubMed ID: 11718743
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease.
Quick A; Tandan R
Curr Rheumatol Rep; 2011 Jun; 13(3):192-8. PubMed ID: 21503696
[TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation.
Rieben R; Roos A; Muizert Y; Tinguely C; Gerritsen AF; Daha MR
Blood; 1999 Feb; 93(3):942-51. PubMed ID: 9920844
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of CX3CL1 (fractalkine) improves experimental autoimmune myositis in SJL/J mice.
Suzuki F; Nanki T; Imai T; Kikuchi H; Hirohata S; Kohsaka H; Miyasaka N
J Immunol; 2005 Nov; 175(10):6987-96. PubMed ID: 16272359
[TBL] [Abstract][Full Text] [Related]
15. Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1γ can result in experimental myositis.
Okiyama N; Ichimura Y; Shobo M; Tanaka R; Kubota N; Saito A; Ishitsuka Y; Watanabe R; Fujisawa Y; Nakamura Y; Murakami A; Kayama H; Takeda K; Fujimoto M
Ann Rheum Dis; 2021 Sep; 80(9):1201-1208. PubMed ID: 33811031
[TBL] [Abstract][Full Text] [Related]
16. Intravenous immunoglobulin therapy for refractory myositis.
Moriguchi M; Suzuki T; Tateishi M; Hara M; Kashiwazaki S
Intern Med; 1996 Aug; 35(8):663-7. PubMed ID: 8894745
[TBL] [Abstract][Full Text] [Related]
17. In vivo deposition of myosin-specific autoantibodies in the hearts of mice with experimental autoimmune myocarditis.
Neumann DA; Lane JR; Wulff SM; Allen GS; LaFond-Walker A; Herskowitz A; Rose NR
J Immunol; 1992 Jun; 148(12):3806-13. PubMed ID: 1602130
[TBL] [Abstract][Full Text] [Related]
18. High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes.
Basta M; Fries LF; Frank MM
Blood; 1991 Jan; 77(2):376-80. PubMed ID: 1985703
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of experimental autoimmune myositis by blocking ICOS-ICOS ligand interaction.
Katsumata Y; Harigai M; Sugiura T; Kawamoto M; Kawaguchi Y; Matsumoto Y; Kohyama K; Soejima M; Kamatani N; Hara M
J Immunol; 2007 Sep; 179(6):3772-9. PubMed ID: 17785814
[TBL] [Abstract][Full Text] [Related]
20. The effect of intravenous immunoglobulins on the progression of experimental autoimmune myocarditis in the rat.
George J; Barshack I; Malka E; Goldberg I; Keren P; Laniado S; Keren G
Exp Mol Pathol; 2001 Aug; 71(1):55-62. PubMed ID: 11502097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
